title: Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
abstract: OBJECTIVE
  The study compared the duration of maintenance of treatment in patients with type 2 diabetes (T2D) using dual therapy with either metformin and sitagliptin (M-Sita) or metformin and a sulphonylurea (M-SU).
  
  
  METHODS
  This observational study included adult patients with T2D who had responded inadequately to metformin monotherapy and therefore had started de-novo treatment with Met-Sita or Met-SU within the previous eight weeks. Patient follow-up and changes to treatment were performed according to their general practitioner's usual clinical practice. The primary outcome was time to change in treatment for whatever cause. HbA1c and symptomatic hypoglycaemia were also documented.
  
  
  RESULTS
  The median treatment duration for patients in the M-Sita group (43.2 months) was significantly longer (P < 0.0001) than in the M-SU group (20.2 months). This difference persisted after adjusting for baseline differences and confounders. A similar reduction in HbA1c was noted in both arms (-0.6%), and the incidence of hypoglycaemia prior to treatment modification was lower with M-Sita (9.7%) than with M-SU (21.0%). Adverse events potentially related to treatment were reported in 2.8% (n = 52) and 2.7% (n = 20) of patients in the M-Sita and M-SU arms, respectively.
  
  
  CONCLUSIONS
  Under everyday conditions of primary diabetes care, dual therapy with M-Sita can be maintained for longer than M-SU. In addition, while efficacy, as measured by changes in HbA1c, was similar between treatments, the incidence of hypoglycaemia was lower in patients taking M-Sita.
authors.affiliation: Department of Endocrinology-Diabetology-Nutrition, Jean-Verdier Hospital, AP-HP, Paris Nord University, CRNH-IdF, CINFO, Bondy, France.
authors.forename: P
authors.initials: P
authors.lastname: Valensi
authors.affiliation: ESSEC, Cergy-Pontoise, France.
authors.forename: G
authors.initials: G
authors.lastname: de Pouvourville
authors.affiliation: MSD France, Courbevoie, France.
authors.forename: N
authors.initials: N
authors.lastname: Benard
authors.affiliation: MSD France, Courbevoie, France.
authors.forename: C
authors.initials: C
authors.lastname: Chanut-Vogel
authors.affiliation: CSD, Boulogne, France.
authors.forename: C
authors.initials: C
authors.lastname: Kempf
authors.affiliation: MSD France, Courbevoie, France. Electronic address: elisabeth.eymard@merck.com.
authors.forename: E
authors.initials: E
authors.lastname: Eymard
authors.affiliation: MSD France, Courbevoie, France.
authors.forename: C
authors.initials: C
authors.lastname: Moisan
authors.affiliation: INSERM U744, Institut Pasteur, Lille, France.
authors.forename: J
authors.initials: J
authors.lastname: Dallongeville
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011446:Prospective Studies; D000068900:Sitagliptin Phosphate / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D008687:Metformin; D000068900:Sitagliptin Phosphate
keywords: DPP-4 inhibitor; Observational study; Type 2 diabetes